Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2011-02-01
2011-02-01
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S198100, C530S351000
Reexamination Certificate
active
07879318
ABSTRACT:
A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The thrombopoietin is administered in a concentration such that the subject's platelet count or production of platelets is not significantly affected.
REFERENCES:
patent: 5498599 (1996-03-01), Choi et al.
patent: 5593666 (1997-01-01), McDonald
patent: 5744587 (1998-04-01), Alaska et al.
patent: 5756083 (1998-05-01), Elliott
patent: 5830647 (1998-11-01), Eaton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5879673 (1999-03-01), Thomas
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5986049 (1999-11-01), Forstrom et al.
patent: 5989538 (1999-11-01), Elliott
patent: 6083913 (2000-07-01), Dower et al.
patent: 6121238 (2000-09-01), Dower et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: 6465430 (2002-10-01), Dower et al.
patent: 6506362 (2003-01-01), Dower et al.
patent: 6531121 (2003-03-01), Brines et al.
patent: 6866998 (2005-03-01), Kitamura et al.
patent: 6887890 (2005-05-01), Fujiwara et al.
patent: 7091207 (2006-08-01), Kukreja
patent: 2001/0026931 (2001-10-01), Tsujimoto et al.
patent: 2003/0158116 (2003-08-01), Dower et al.
patent: 2003/0162724 (2003-08-01), Fujiwara et al.
patent: 2003/0195231 (2003-10-01), Takemoto et al.
patent: 2003/0195234 (2003-10-01), Dickerson et al.
patent: 2004/0063764 (2004-04-01), Takemoto et al.
patent: 2004/0071688 (2004-04-01), Carr et al.
patent: 2004/0082626 (2004-04-01), Takemoto et al.
patent: 2004/0136980 (2004-07-01), Soltis et al.
patent: 2004/0198663 (2004-10-01), Baker et al.
patent: 95/21626 (1995-08-01), None
patent: 96/40217 (1996-12-01), None
patent: 97/26907 (1997-07-01), None
patent: 2004/096154 (2004-11-01), None
patent: 2005/041867 (2005-05-01), None
patent: 2007/010954 (2007-01-01), None
patent: 2007/011056 (2007-01-01), None
Basser et al, The Lancet, 348:1279, 1996.
Bolli et al., in their article “Myocaridal Protection at a Crossroads; the need for translation into clinical therapy”, Circulation Research, 1994.
Vadhan-Raj et al., Seminars in Hematology 35(3):261-268, 1998.
Kaushansky, Trends Endocrinol. Metab. 1997 8:45-50.
Calvert et al., Cardiovascular Research, 77:2-3, 2008.
Baker et al. “Preconditioning in Immature Rabbit Hearts,” Circulation (1999) 99:1249-1254.
Baker et al. “Resistance to Myocardial Ischemia in Five Rat Strains,” Am. J. Physiol. Heart Circ. Physiol. (2000) 278:H1395-H1400.
Bolli et al. “Myocardial Protection at a Crossroads,” Circ. Res. (2004) 95:125-134.
Case et al. “The Pharmokinetics and Pharmodynamis of GW395058 . . . ” Stem Cells (2000) 18:360-365.
Clements-Jewery et al. “Independent Contribution of Catecholamines to Arrhythmogenesis . . . ” British J. Pharmacology (2002) 135:807-815.
Cotton et al. “Rise of Circulating Thrombopoietin Following Cardiothoracic Surgery . . . ” Thromb. Haemost. (2003) 89:538-543.
Cwirla et al. “Peptide Agonist of the Thrombopoietin Receptor . . . ” Science (1997) 276:1696-1699.
De Serres et al. “Pharmokinetics and Hematological Effects . . . ” Stem Cells (1999) 17:316-326.
De Serres et al. “Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 . . . ” Stem Cells (1999) 17:203-209.
Dobado-Berrios et al. “Plasma Thrombopoietin Level after Liver Transplantation . . . ” Intensive Care Med. (2000) 26:804-807.
Douglas et al. “Thrombopoietin Administered During Induction Chemotherapy to Patients . . . ” Hematopathology (2002) 117:844-850.
Eells et al. “Increased Mitochondrial KATP Channel Activity During Chronic . . . ” Circ. Res. (2000) 87:915-921.
Elliot et al. Nature Biotechnology (2003) 21:414-421.
Erickson-Miller et al. “Discovery and Characterization of a Selective, Nonpeptidyl Thrombopoietin Receptor Agonist,” Exp. Hematology (2005) 33:85-93.
Farkas et al. “Limited Antifibrillatory Effectiveness of Clinically Relevant Concentrations . . . ” J. Cardio. Pharmacology (2002) 39:412-424.
Gajewski et al. “Use of Thrombopoietin in Combination with Chemotherapy and Granulocyte . . . ” Biology of Blood & Marrow Transplantation (2002) 8:550-556.
Goldberg, J. “Technology Evaluation: Thrombopoietin, Genentech/Pharmacia & Upjohn,” Molecular Therapeutics (2000) 2:2:211-215.
Harada et al. “Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor . . . ” J. Pharm. Pharmacol. (2000) 52:321-325.
Ide et al. “Peg-rHuMGDF Ameliorates Thrombocytopenia in Carboplatin-treated Rats . . . ” Int. J. Hematology (1999) 70:91-96.
Inagaki et al. “Induction of Megakaryocytopoiesis and Thrombocytopoiesis by JTZ-132 . . . ” Blood (2004) 104:58-64.
Konorev et al. “Cell-Permeable Superoxide Dismutase and Glutathione Peroxidase Mimetics . . . ” Arch. Biochem. & Biophysics (1999) 368:2:421-428.
Linker et al. “Recombinant Human Thrombopoietin Augments Mobilization of Peripheral Blood Progenitor . . . ” Bio. Blood & Marrow Transplantation (2003) 9:405-413.
Nash et al. “A Phase I Trial of Recombinant Human Thrombopoietin in Patients with Delayed Platelet . . . ” ASBMT (1999) 25-34.
Orita et al. “A Novel Therapeutic Approach for Thrombocytopenia by Minibody Agonist . . . ” Blood (2005) 105:562-566.
Senaran et al. “Thrombopoietin and Mean Platelet Volumen in Coronary Artery Disease,” (2001) Clin. Cardio. 24:405-408.
Shi et al. “Acute Cardioprotective Effects of Erythropoietin in Infant Rabbits are Mediated . . . ” Basic Res. Cardio. (2004) 99:173-182.
Somlo et al. “Recombinant Human Thrombopoietin in Combination with Granulocyte Colongy-Stimulating Factor . . . ” Blood (1999) 93:9:2798-2806.
Vadhan-Raj et al. “Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recominant . . . ” Ann. Intern. Med. (1997) 126:9:673-681.
Vadhan-Raj et al. “Importance of Predosing of Recombinant Human Thrombopoietin to Reduce . . . ” J. Clin. Oncology (2003) 21:16:3158-3167.
Vadhan-Raj et al. “Safety and Efficacy of Transfusions of Autologous Cryopreserved Platelets . . . ” Lancet (2002) 359:2145-2152.
Vadhan-Raj et al. “Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe . . . ” Ann. Intern. Med. (2000) 132:364-368.
Van Der Loo et al. “Megakaryocytes and Platelets in Vascular Disease,” Bailliere's Clin. Haematology (1997) 10:1:109-123.
Wang et al. “Pharmacodynamics and Drug Action,” Clin. Pharmacol. Ther. (2004) 76:623-638.
Webb et al. “Polymorphisms in the Thrombopoietin gene are Associated with Risk of Myocardial Infarction . . . ” Artherosclerosis (2001) 154:703-711.
Webb et al. “The 4830C> A Polymorphism within Intron 5 Affects the Pattern of Alternative Splicing . . . ” Exp. Hematology (2003) 31:488-494.
Vadhan-Raj S, “Recombinant Human Thrombopoietin: Clinical Experience and In Vivo Biology”, Seminars in Hematology, Philadelphia, PA, US, Jul. 1998, 261-268, vol. 35, No. 3.
Vadhan-Raj S, et al, “Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia”, Journal of Clinical Oncology, 2003, 3158-3167, vol. 21, No. 16.
Neelis K J, et al, “The Efficacy of Single-Dose Administration of Thrombopoietin with Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys”, Blood, 1997, 2565-2573, vol. 90, No. 7.
Amano Hideki et al, “Thrombopoietin Gene Transfer-Mediated Enhancement of Angiogenic Responses to Acute Ischemia”, Circulation Research, 2005, 337-345, vol. 97, No. 4.
ISR and Written Opinion of the
Baker John E.
Shi Yang
MCW Research Foundation, Inc.
Quarles & Brady LLP
Spector Lorraine
LandOfFree
Method of reducing the effects of ischemia by administration... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing the effects of ischemia by administration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing the effects of ischemia by administration... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626255